The Laboratory tubes

Product

High definition 28523-86-6 - Mitomycin C 50-07-7 Antibiotic Antineoplastic – Neore

Short Description:


Product Detail

Product Tags

Related Video

Feedback (2)

Along with the "Client-Oriented" small business philosophy, a rigorous high-quality handle system, highly developed producing machines and a powerful R&D group, we always supply high-quality products and solutions, fantastic services and aggressive costs for 96829-58-2, Pal-GHK palmitoyl tripeptide-1, ghk-cu, Welcome to visit our company and factory. Please feel free to get in touch with us if you need any further assistance.
High definition 28523-86-6 - Mitomycin C 50-07-7 Antibiotic Antineoplastic – Neore Detail:

Payment: T/T, L/C
Product Origin: China
Shipping Port: Beijing/Shanghai/Hangzhou
Production capacity: 5kg/month
Order(MOQ): 10g
Lead Time: 3 Working Days
Storage condition: Stored in cool, dry place, room temperature.
Package material: vial
Package size: 10g/drum
Safety information:  UN 2811 6.1/ PG 1

Mitomycin C

Description

Mitomycin C is a mitomycin that is used as a chemotherapeutic agent by virtue of its antitumour activity.

It is given intravenously to treat upper gastro-intestinal cancers (e.g. esophageal carcinoma), anal cancers, and breast cancers, as well as by bladder instillation for superficial bladder tumours.

Mitomycin C is used in cancers, particularly bladder cancers and intraperitoneal tumours.

Mitomycin C is used in eye surgery where mitomycin C 0.02% is applied topically to prevent scarring during glaucoma filtering surgery and to prevent haze after PRK or LASIK; mitomycin C has also been shown to reduce fibrosis in strabismus surgery.

Mitomycin C is used in esophageal and tracheal stenosis where application of mitomycin C onto the mucosa immediately following dilatation will decrease re-stenosis by decreasing the production of fibroblasts and scar tissue.

Specification (USP/EP)

Item

Specification

Appearance

Blue-violet, crystalline powder

Identification

IR: The IR spectrum of the sample corresponds to the spectrum of reference standard
  HPLC: The retention time of the major peak of the sample solution corresponds to that of the standard solution, as obtained in the Assay
pH

6.0~7.5

Water

Not more than 2.5%

Crystallinity

Should conforms

Related Substances
Albomitomycin C

(EP Impurity D)

Not more than 0.5%

Mitomycin B

(EP Impurity C)

Not more than 0.5%

Cinnamamide

(EP Impurity A)

Not more than 0.5%

Mitomycin A

(EP Impurity B)

Not more than 0.5%

Any Individual Unspecified Impurity

Not more than 0.5%

Total Impurities

Not more than 2.0%

Residual Solvents
Methanol

Not more than 3000 ppm

Methylene Chloride

Not more than 600 ppm

Ethyl Acetate

Not more than 5000 ppm

Bacterial Endotoxins

Not more than 10 EU/mg

Assay

Not less than 970 mg/g of Mitomycin


Product detail pictures:

High definition 28523-86-6 - Mitomycin C 50-07-7 Antibiotic Antineoplastic – Neore detail pictures


Related Product Guide:

Adhering for the theory of "quality, services, performance and growth", we have received trusts and praises from domestic and worldwide shopper for High definition 28523-86-6 - Mitomycin C 50-07-7 Antibiotic Antineoplastic – Neore , The product will supply to all over the world, such as: Turin, Denver, Saudi Arabia, Each product is carefully made, it will make you satisfied. Our merchandise in the production process have got strictly monitored, because it is only to supply you the best quality, we'll feel confident. High production costs but low prices for our long-term cooperation. You can have a variety choices and the value of all types are same reliable. If you have any question, do not hesitate to ask us.
  • It can be said that this is a best producer we encountered in China in this industry, we feel lucky to work with so excellent manufacturer.
    5 Stars By ron gravatt from Surabaya - 2017.05.31 13:26
    The company has a good reputation in this industry, and finally it tured out that choose them is a good choice.
    5 Stars By Fernando from Johor - 2017.06.19 13:51